> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Orphan Status for Pancreatic Cancer Drug
- URL: https://www.fdaweb.com/orphan-status-for-pancreatic-cancer-drug/
- Published: 2023-10-04T12:00:00.000Z
- Updated: 2026-09-14T19:00:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155481

FDA has granted Noxopharm an Orphan Drug Designation for CRO-67, a drug candidate for treating pancreatic cancer. The designation was based on data that showed that CRO-67 killed tumor cells as well as barrier cells in samples taken from patients who had their tumors surgically removed. The company also says that in a mice study, the drug significantly reduced tumor volume *in vivo* by an average of 56.7% versus untreated controls. Additionally, CRO-67 slowed down by 48% the rate at which the tumors grew.

Noxopharm says pancreatic cancer is set to become the second leading cause of cancer-related deaths in the U.S. by 2040, and has a very poor five-year survival rate of about 9% from the time of diagnosis.